Schrödinger Files 2024 Annual Meeting Proxy Supplement

TL;DR

Schrödinger filed proxy docs for June 18th meeting - check for updates!

AI Summary

Schrödinger, Inc. is filing a supplemental proxy statement for its 2024 Annual Meeting of Stockholders, scheduled for June 18, 2024. This filing provides additional materials related to the meeting, which will be held at 1540 Broadway, New York, NY. The company is registered under SIC code 2834 for Pharmaceutical Preparations.

Why It Matters

This filing provides updated information to shareholders regarding the upcoming annual meeting, ensuring they have the latest details before casting their votes on important company matters.

Risk Assessment

Risk Level: low — This is a routine supplemental filing for an annual shareholder meeting and does not appear to contain unusual or high-risk information.

Key Players & Entities

• Schrödinger, Inc. (company) — Registrant and filer of the proxy statement
• June 18, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders
• 1540 Broadway, New York, NY (location) — Business and mailing address of Schrödinger, Inc.
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Filing Documents

• sdgr-2024proxystatementsup.htm (DEFA14A) — 15KB
• schrodingerlogo_horizontala.jpg (GRAPHIC) — 559KB
• 0001490978-24-000048.txt ( ) — 786KB

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to 240.14a-12 SCHRDINGER, INC. (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check all boxes that apply) x No fee required o Fee paid previously with preliminary materials o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SUPPLEMENT TO PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS To be held on Tuesday, June 18, 2024 Schrdinger, Inc. (the "Company") is filing this supplement on May 30, 2024 to update biographical information for Ramy Farid, a director nominee and the Company's president and chief executive officer, contained in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 25, 2024 (the "Proxy Statement"), and made available to the Company's stockholders in connection with the solicitation of proxies on behalf of the board of directors of the Company for its annual meeting of stockholders to be held on June 18, 2024, or any adjournment or postponement thereof. The Company urges you to read the Proxy Statement and this supplement in their entirety. To the extent that information in this supplement differs from or updates information contained in the Proxy Statement, the information in this supplement is more current. Updates to Ramy Farid's Biographical Information As of the date of this supplement, Dr. Farid serves as a director at three public companies Schrdinger, Inc., Vir Biotechnology, Inc. and Structure Therapeutics Inc. ("Structure"). Dr. Farid's term on the board of directors of Structure will expire on June 25, 2024 at Structure's 2024 annual general meeting of shareholders, and Dr. Farid is not standing for re-election to Structure's board of directors. Once Dr. Farid's term on the board of directors of Structure ends on June 25, 2024, Dr. Farid will be serving on only two public company boards, one of which will be the Company's board of directors. May 30, 2024

View Full Filing

View this DEFA14A filing on SEC EDGAR